ECSP19034535A - Inhibidores de la magl - Google Patents
Inhibidores de la maglInfo
- Publication number
- ECSP19034535A ECSP19034535A ECSENADI201934535A ECDI201934535A ECSP19034535A EC SP19034535 A ECSP19034535 A EC SP19034535A EC SENADI201934535 A ECSENADI201934535 A EC SENADI201934535A EC DI201934535 A ECDI201934535 A EC DI201934535A EC SP19034535 A ECSP19034535 A EC SP19034535A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- compositions
- magl inhibitors
- magl
- useful
- Prior art date
Links
- 102100029814 Monoglyceride lipase Human genes 0.000 title abstract 2
- 101710116393 Monoglyceride lipase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423102P | 2016-11-16 | 2016-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19034535A true ECSP19034535A (es) | 2019-05-31 |
Family
ID=62145825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201934535A ECSP19034535A (es) | 2016-11-16 | 2019-05-15 | Inhibidores de la magl |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11059822B2 (OSRAM) |
| EP (1) | EP3541820B1 (OSRAM) |
| JP (1) | JP7042468B2 (OSRAM) |
| KR (1) | KR20190080935A (OSRAM) |
| CN (1) | CN110267962B (OSRAM) |
| AU (1) | AU2017361253B2 (OSRAM) |
| BR (1) | BR112019009880A2 (OSRAM) |
| CA (1) | CA3043617A1 (OSRAM) |
| CL (1) | CL2019001336A1 (OSRAM) |
| CO (1) | CO2019004945A2 (OSRAM) |
| CR (1) | CR20190239A (OSRAM) |
| DO (1) | DOP2019000118A (OSRAM) |
| EA (1) | EA038150B1 (OSRAM) |
| EC (1) | ECSP19034535A (OSRAM) |
| ES (1) | ES2952582T3 (OSRAM) |
| IL (1) | IL266547B (OSRAM) |
| JO (1) | JOP20190107A1 (OSRAM) |
| MA (1) | MA46855A (OSRAM) |
| MX (1) | MX389627B (OSRAM) |
| NI (1) | NI201900049A (OSRAM) |
| PE (1) | PE20191145A1 (OSRAM) |
| PH (1) | PH12019501079A1 (OSRAM) |
| RU (1) | RU2019115784A (OSRAM) |
| TN (1) | TN2019000149A1 (OSRAM) |
| UA (1) | UA125523C2 (OSRAM) |
| WO (1) | WO2018093949A1 (OSRAM) |
| ZA (1) | ZA201903099B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109496213B (zh) * | 2016-05-12 | 2022-03-04 | H.隆德贝克有限公司 | 螺环化合物及其制备和使用方法 |
| JOP20190108B1 (ar) | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| HUE064559T2 (hu) | 2016-11-16 | 2024-03-28 | H Lundbeck As | MAGL inhibitor kristályos formája |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| RS64006B1 (sr) | 2017-05-23 | 2023-03-31 | H Lundbeck As | Pirazol magl inhibitori |
| BR112020003946A2 (pt) | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| ES2952332T3 (es) | 2017-08-29 | 2023-10-30 | H Lundbeck As | Compuestos espirocíclicos y sus métodos de preparación y uso |
| KR20210033504A (ko) * | 2018-07-19 | 2021-03-26 | 화이자 인코포레이티드 | Magl 억제제로서 헤테로환형 스피로 화합물 |
| HUE067912T2 (hu) | 2018-08-13 | 2024-11-28 | Hoffmann La Roche | Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok |
| KR20230004622A (ko) | 2020-04-21 | 2023-01-06 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제의 합성 |
| US11434222B2 (en) | 2020-11-13 | 2022-09-06 | H. Lundbeck A/S | MAGL inhibitors |
| US20250084065A1 (en) | 2021-12-29 | 2025-03-13 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN119137114A (zh) | 2022-05-04 | 2024-12-13 | H.隆德贝克有限公司 | 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1003002A (en) | 1910-10-10 | 1911-09-12 | Gustave J Martel | Tire-patching device. |
| WO2002070523A1 (en) | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| JP2009514935A (ja) * | 2005-11-05 | 2009-04-09 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
| EP2065369A4 (en) | 2006-08-23 | 2011-12-28 | Astellas Pharma Inc | UREA CONNECTION OR SALT THEREOF |
| AU2009221860A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| FR2941696B1 (fr) | 2009-02-05 | 2011-04-15 | Sanofi Aventis | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| CA2775703C (en) | 2009-09-29 | 2014-07-08 | Polyone Corporation | Polyester articles having simulated metallic or pearlescent appearance |
| HUE043962T2 (hu) | 2009-10-23 | 2019-09-30 | Janssen Pharmaceutica Nv | Diszubsztituált oktahidro-pirrolo[3,4-C]pirrolok mint orexin receptor modulátorok |
| CA2791672A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| JP2014005245A (ja) * | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| HRP20191937T1 (hr) | 2012-09-25 | 2020-01-10 | F. Hoffmann - La Roche Ag | Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti |
| US9828379B2 (en) * | 2013-07-03 | 2017-11-28 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
| SG11201607920RA (en) * | 2014-04-04 | 2016-10-28 | X Rx Inc | Substituted spirocyclic inhibitors of autotaxin |
| US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2016149401A2 (en) | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| MX2017014344A (es) | 2015-05-11 | 2018-04-11 | Abide Therapeutics Inc | Metodos para el tratamiento de la inflacion o el dolor neuropatico. |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| US10519134B2 (en) | 2015-11-20 | 2019-12-31 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| TWI738753B (zh) | 2016-03-31 | 2021-09-11 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| CN109496213B (zh) | 2016-05-12 | 2022-03-04 | H.隆德贝克有限公司 | 螺环化合物及其制备和使用方法 |
| JOP20190049A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| HUE064559T2 (hu) | 2016-11-16 | 2024-03-28 | H Lundbeck As | MAGL inhibitor kristályos formája |
| JOP20190108B1 (ar) | 2016-11-16 | 2023-09-17 | H Lundbeck As | تركيبات صيدلانية |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CN117510468A (zh) | 2017-03-13 | 2024-02-06 | 灵北拉荷亚研究中心公司 | 双重magl和faah抑制剂 |
| RS64006B1 (sr) | 2017-05-23 | 2023-03-31 | H Lundbeck As | Pirazol magl inhibitori |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| BR112020003946A2 (pt) | 2017-08-29 | 2020-09-08 | Lundbeck La Jolla Research Center, Inc. | compostos de espirociclo e métodos para produzir e usar os mesmos |
| ES2952332T3 (es) | 2017-08-29 | 2023-10-30 | H Lundbeck As | Compuestos espirocíclicos y sus métodos de preparación y uso |
| US11434222B2 (en) | 2020-11-13 | 2022-09-06 | H. Lundbeck A/S | MAGL inhibitors |
-
2017
- 2017-06-16 JO JOP/2019/0107A patent/JOP20190107A1/ar unknown
- 2017-11-15 UA UAA201905617A patent/UA125523C2/uk unknown
- 2017-11-15 BR BR112019009880A patent/BR112019009880A2/pt not_active IP Right Cessation
- 2017-11-15 JP JP2019523671A patent/JP7042468B2/ja active Active
- 2017-11-15 MA MA046855A patent/MA46855A/fr unknown
- 2017-11-15 AU AU2017361253A patent/AU2017361253B2/en not_active Ceased
- 2017-11-15 EP EP17871458.0A patent/EP3541820B1/en active Active
- 2017-11-15 WO PCT/US2017/061870 patent/WO2018093949A1/en not_active Ceased
- 2017-11-15 MX MX2019005773A patent/MX389627B/es unknown
- 2017-11-15 US US16/349,047 patent/US11059822B2/en active Active
- 2017-11-15 CN CN201780083651.3A patent/CN110267962B/zh active Active
- 2017-11-15 TN TNP/2019/000149A patent/TN2019000149A1/en unknown
- 2017-11-15 CA CA3043617A patent/CA3043617A1/en not_active Abandoned
- 2017-11-15 EA EA201991029A patent/EA038150B1/ru unknown
- 2017-11-15 ES ES17871458T patent/ES2952582T3/es active Active
- 2017-11-15 PE PE2019001017A patent/PE20191145A1/es unknown
- 2017-11-15 RU RU2019115784A patent/RU2019115784A/ru unknown
- 2017-11-15 KR KR1020197017201A patent/KR20190080935A/ko not_active Ceased
- 2017-11-15 CR CR20190239A patent/CR20190239A/es unknown
-
2019
- 2019-05-12 IL IL266547A patent/IL266547B/en unknown
- 2019-05-14 CO CONC2019/0004945A patent/CO2019004945A2/es unknown
- 2019-05-14 DO DO2019000118A patent/DOP2019000118A/es unknown
- 2019-05-15 PH PH12019501079A patent/PH12019501079A1/en unknown
- 2019-05-15 EC ECSENADI201934535A patent/ECSP19034535A/es unknown
- 2019-05-16 CL CL2019001336A patent/CL2019001336A1/es unknown
- 2019-05-16 NI NI201900049A patent/NI201900049A/es unknown
- 2019-05-17 ZA ZA2019/03099A patent/ZA201903099B/en unknown
-
2021
- 2021-06-09 US US17/343,227 patent/US11691975B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900049A (es) | Inhibidores de la magl | |
| NI202000080A (es) | Inhibidores de magl | |
| CO2019005059A2 (es) | Inhibidores de magl | |
| CO2019005038A2 (es) | Inhibidores de magl | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| CO2020001715A2 (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| CO2020001724A2 (es) | Compuestos espirocíclicos y sus métodos de preparación y uso referencia cruzada | |
| CL2019003397A1 (es) | Inhibidores pirazólicos de magl. | |
| MX2022006862A (es) | Inhibidores duales de magl y faah. |